Parkinson Disease

Panelists discuss how medical professionals determine the most appropriate treatment options for patients with advanced Parkinson disease and the challenges patients face as their disease progresses over time.

Fernando L. Pagan, MD, discussed how continuous subcutaneous apomorphine infusion impacts long-term motor fluctuations in Parkinson disease, highlighting InfusON extension study findings on uninterrupted "good ON" time and reduced "OFF" periods as evidence of its real-world efficacy.

The chief scientific officer of the Parkinson’s Foundation discussed the foundation’s efforts to integrate whole genome sequencing into PD GENEration and expand access across diverse global populations. [WATCH TIME: 4 minutes]

Findings from a phase 3 study revealed that patients with Parkinson disease switching to IPX203 had greater benefits in good ON time when also taking lower doses of dopamine agonists.

Presented at the 2025 AD/PD Conference, the study incorporates patient engagement in its design and implementation, focusing on optimizing study accessibility, reducing burden, and evaluating glovadalen’s potential as an adjunctive treatment for PD.

A pilot study, presented at the 2025 AD/PD conference, evaluating the CUE1 device suggests it may help improve motor symptoms and reduce fall risk in patients with Parkinson disease.

An expert discusses D1 receptor agonists that reduce negative symptoms and the increasing availability of recent and upcoming PUMP options for Parkinson disease treatment.

An expert discusses the importance of collaborating with patients, emphasizing the value of leading with data when educating them on the efficacy of treatments, and highlights the role of providers in supporting patients as they discover the medications and supplements that work best for them, while advocating for and protecting patients to ensure they can seek the best quality of life.

An expert discusses the various forms of therapy offering nutritional support, including exercise and supplements, emphasizing that supplemental therapy, along with medication, is most effective, and highlights the potential benefits of the Mediterranean diet for Parkinson disease.

An expert discusses how patients with dyskinesia are well suited to use pumps and how subcutaneous dopamine agonists avoid the issues previously associated with oral dopamine agonists.

An expert discusses upcoming advancements in Parkinson disease treatments, including the potential release of the ND0612 pump later this year, demonstrating efficacy comparable to oral carbidopa/levodopa, the dopamine agonist tavapadon, CVN424 as a novel therapy not targeting the dopamine pathway, and ongoing stem cell and gene therapy developments, with stem cells capable of creating dopamine-producing cells entering phase 3 studies.

An expert discusses the extended form of carbidopa/levodopa (Crexont) for managing OFF episodes, highlighting trial results that show decreased OFF time and increased ON time, as well as the use of subcutaneous loading of medications in Parkinson disease, which was well tolerated with skin issues as the main adverse effects and resulted in increased ON time without worsening dyskinesia.

An expert discusses how providers can accurately track episodes of OFF and dyskinesia, highlighting their impact on patients physically, socially, and psychologically, including the challenges dyskinesia poses for sleep and fine motor tasks.

The professor of neurology at Northwestern University Feinberg School of Medicine discussed the NSD-ISS and its potential to refine PD diagnosis and clinical trial selection through biomarker-driven staging.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on Parkinson disease.

A physician assistant specializing in Parkinson disease discussed advancements in neurology aimed at enabling personalized treatment, continuous monitoring, and improved disease management. [WATCH TIME: 4 minutes]

The approval was based on data from the ADAPT-PD trial, a prospective study that laid the foundation for aDBS use in a real-world clinical environment.

More than 90% of participants had Parkinson's disease mild cognitive impairment (PD-MCI), highlighting TAK-071’s potential for treating early-stage cognitive decline in Parkinson disease.

The movement disorder nurse practitioner at Stony Brook Medicine talked about the growing role of artificial intelligence in neurology and emerging treatments for Parkinson disease.

The nurse practitioner at the Parkinson’s and Movement Disorders Center at Stony Brook Medicine discussed the increasing role of artificial intelligence in neurology, specifically movement disorders. [WATCH TIME: 5 minutes]

The chair of neurosurgery at the University of Arizona talked about the newly approved infusion therapy that offers continuous medication delivery to improve both motor and non-motor symptoms in Parkinson disease. [WATCH TIME: 5 minutes]

The director of the Parkinson’s Disease and Movement Disorders Center of Boca Raton, Florida, commented on the promising safety of SPN-830 and who may be best suited for treatment with the newly approved therapy. [WATCH TIME: 4 minutes]

Julie Pilitsis, MD, PhD, MBA, chair of neurosurgery at The University of Arizona Tucson, discussed the impact of a newly approved continuous infusion therapy for Parkinson disease.

The 32-week study will enroll 15–20 adults aged 18–80 with Parkinson's-related hyposmia, featuring a 24-week treatment period of twice-daily CYR-064 nasal sprays.

The movement disorders nurse practitioner at The Ohio State University Wexner Medical Center talked about a meeting that equips nurse practitioners and physician assistants to improve movement disorder patient care. [WATCH TIME: 5 minutes]